Dublin, Jan. 22, 2026 (GLOBE NEWSWIRE) -- The "Optical Genome Mapping Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031" has been added to ResearchAndMarkets.com's ...
A phase II study of hyper-CVAD with blinatumomab (blina) and inotuzumab ozogamicin (INO) for newly diagnosed Philadelphia chromosome (Ph)–negative B-cell acute lymphoblastic leukemia (ALL).
Jack Rogers, Ph.D., Professor of Biomedical Engineering, was recently awarded a grant from the New Zealand Royal Society Te Apārangi through the Catalyst International Leadership Fellowship. The ...
SAN DIEGO, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced Bionano Symposium 2026, the premier global event for the optical genome mapping (OGM) community. This ...
Bionano announced a significant study published in the American Journal of Hematology demonstrating the utility of optical genome mapping (OGM) in detecting structural variants associated with ...
SAN DIEGO, May 02, 2025 (GLOBE NEWSWIRE) -- Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics, Inc. (BNGO) that offers CLIA-certified laboratory developed tests (LDTs) based on ...
SAN DIEGO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO) today announced a peer-reviewed publication from a team led by Manon Delafoy from the Institut Necker Enfants Malades (INEM) ...
A study in The Journal of Molecular Diagnostics assessing the efficacy of optical genome mapping (OGM) in a cohort of patients with acute leukemia has demonstrated that OGM provided reliable and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results